 [1m([0morchestrator-bleeding-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the [0m
[34mrisk of bleeding?[0m
 [1m([0morchestrator-bleeding-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the risk of bleeding?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the [0m
[32mrisk of bleeding?[0m
 [1m([0morchestrator-bleeding-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the risk of bleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"ERYTHROMYCIN ETHYLSUCCINATE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: information_for_patients: Information for Patients Patients should be counseled that antibacterial drugs including Ery-Ped should only be used to treat bacterial [0m
[31minfections. They do not treat viral infections [0m[1;31m([0m[31me.g., the common cold[0m[1;31m)[0m[31m. When Ery-Ped is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better [0m
[31mearly in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m decrease the effectiveness of the immediate [0m
[31mtreatment and [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m increase the likelihood that bacteria will develop resistance and will not be treatable by Ery-Ped or other antibacterial drugs in the future. Diarrhea is a common problem caused by [0m
[31mantibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools [0m[1;31m([0m[31mwith or without stomach cramps [0m
[31mand fever[0m[1;31m)[0m[31m even as late as two or more months after having taken the last dose of the antibiotic. ERYTHROMYCIN ETHYLSUCCINATE: information_for_patients: If this occurs, patients should contact their [0m
[31mphysician as soon as possible.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: spl_unclassified_section: Rx only To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ery-Ped and other antibacterial drugs, [0m
[31mEry-Ped should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: drug_interactions: Drug Interactions Theophylline Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in [0m
[31mserum theophylline levels and potential theophylline toxicity. In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient [0m
[31mis receiving concomitant erythromycin therapy. There have been published reports suggesting that when oral erythromycin is given concurrently with theophylline there is a decrease in erythromycin [0m
[31mserum concentrations of approximately [0m[1;31m35[0m[31m%. The mechanism by which this interaction occurs is unknown. The decrease in erythromycin concentrations due to co-administration of theophylline could result [0m
[31min subtherapeutic concentrations of erythromycin. ERYTHROMYCIN ETHYLSUCCINATE: drug_interactions: Hypotension, bradyarrhythmias, and lactic acidosis have been observed in patients receiving concurrent[0m
[31mverapamil, belonging to the calcium channel blockers drug class. Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels. There have been [0m
[31mreports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly. Increased anticoagulation effects due to interactions of erythromycin with various oral [0m
[31manticoagulants may be more pronounced in the elderly. Erythromycin is a substrate and inhibitor of the 3A isoform subfamily of the cytochrome p450 enzyme system [0m[1;31m([0m[31mCYP3A[0m[1;31m)[0m[31m. ERYTHROMYCIN ETHYLSUCCINATE: [0m
[31mdrug_interactions: Coadministration of erythromycin and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both the [0m
[31mtherapeutic and adverse effects of the concomitant drug. Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored [0m
[31mclosely in patients concurrently receiving erythromycin. The following are examples of some clinically significant CYP3A based drug interactions. Interactions with other drugs metabolized by the CYP3A[0m
[31misoform are also possible. ERYTHROMYCIN ETHYLSUCCINATE: drug_interactions: The following CYP3A based drug interactions have been observed with erythromycin products in post-marketing experience: [0m
[31mErgotamine/dihydroergotamine Post-marketing reports indicate that co-administration of erythromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by [0m
[31mvasospasm and ischemia of the extremities and other tissues including the central nervous system. Concomitant administration of erythromycin with ergotamine or dihydroergotamine is contraindicated [0m
[1;31m([0m[31msee CONTRAINDICATIONS [0m[1;31m)[0m[31m. Triazolobenzodiazepines [0m[1;31m([0m[31msuch as triazolam and alprazolam[0m[1;31m)[0m[31m and Related Benzodiazepines Erythromycin has been reported to decrease the clearance of triazolam and midazolam, [0m
[31mand thus, may increase the pharmacologic effect of these benzodiazepines. ERYTHROMYCIN ETHYLSUCCINATE: drug_interactions: HMG-CoA Reductase Inhibitors Erythromycin has been reported to increase [0m
[31mconcentrations of HMG-CoA reductase inhibitors [0m[1;31m([0m[31me.g., lovastatin and simvastatin[0m[1;31m)[0m[31m. Rare reports of rhabdomyolysis have been reported in patients taking these drugs concomitantly. Sildenafil [0m[1;31m([0m[31mViagra[0m[1;31m)[0m[31m [0m
[31mErythromycin has been reported to increase the systemic exposure [0m[1;31m([0m[31mAUC[0m[1;31m)[0m[31m of sildenafil. Reduction of sildenafil dosage should be considered. [0m[1;31m([0m[31mSee Viagra package insert.[0m[1;31m)[0m[31m There have been spontaneous or [0m
[31mpublished reports of CYP3A based interactions of erythromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine,[0m
[31mand bromocriptine. ERYTHROMYCIN ETHYLSUCCINATE: drug_interactions: Concomitant administration of erythromycin with cisapride, pimozide, astemizole, or terfenadine is contraindicated. [0m[1;31m([0m[31mSee [0m
[31mCONTRAINDICATIONS .[0m[1;31m)[0m[31m In addition, there have been reports of interactions of erythromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate. [0m
[31mErythromycin has been reported to significantly alter the metabolism of the nonsedating antihistamines terfenadine and astemizole when taken concomitantly. Rare cases of serious cardiovascular adverse[0m
[31mevents, including electrocardiographic QT/QT c interval prolongation, cardiac arrest, torsades de pointes, and other ventricular arrhythmias have been observed. [0m[1;31m([0m[31mSee CONTRAINDICATIONS .[0m[1;31m)[0m[31m In addition, [0m
[31mdeaths have been reported rarely with concomitant administration of terfenadine and erythromycin.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: product_ndc         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: brand_name         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: package_ndc         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: spl_product_data_elements: Ery-Ped Erythromycin Ethylsuccinate CARAMEL POLYSORBATE [0m[1;31m80[0m[31m SODIUM CITRATE, UNSPECIFIED FORM SUCROSE XANTHAN GUM ERYTHROMYCIN [0m
[31mETHYLSUCCINATE ERYTHROMYCIN Ery-Ped Erythromycin Ethylsuccinate CARAMEL POLYSORBATE [0m[1;31m80[0m[31m SODIUM CITRATE, UNSPECIFIED FORM SUCROSE XANTHAN GUM ERYTHROMYCIN ETHYLSUCCINATE ERYTHROMYCIN         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: general_precautions: In one cohort of [0m[1;31m157[0m[31m newborns who were given erythromycin for pertussis prophylaxis, seven neonates [0m[1;31m([0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m developed symptoms of non-bilious [0m
[31mvomiting or irritability with feeding and were subsequently diagnosed as having IHPS requiring surgical pyloromyotomy . A possible dose-response effect was described with an absolute risk of IHPS of [0m
[1;31m5.1[0m[31m% for infants who took erythromycin for [0m[1;31m8[0m[31m-[0m[1;31m14[0m[31m days and [0m[1;31m10[0m[31m% for infants who took erythromycin for [0m[1;31m15[0m[31m-[0m[1;31m21[0m[31m days. [0m[1;31m2[0m[31m Since erythromycin may be used in the treatment of conditions in infants which are [0m
[31massociated with significant mortality or morbidity [0m[1;31m([0m[31msuch as pertussis or neonatal Chlamydia trachomatis infections[0m[1;31m)[0m[31m, the benefit of erythromycin therapy needs to be weighed against the potential risk [0m
[31mof developing IHPS. Parents should be informed to contact their physician if vomiting or irritability with feeding occurs. ERYTHROMYCIN ETHYLSUCCINATE: precautions: Prolonged or repeated use of [0m
[31merythromycin may result in an overgrowth of nonsusceptible bacteria or fungi. If superinfection occurs, erythromycin should be discontinued and appropriate therapy instituted. When indicated, incision[0m
[31mand drainage or other surgical procedures should be performed in conjunction with antibiotic therapy. Observational studies in humans have reported cardiovascular malformations after exposure to drug [0m
[31mproducts containing erythromycin during early pregnancy. Information for Patients Patients should be counseled that antibacterial drugs including Ery-Ped should only be used to treat bacterial [0m
[31minfections. They do not treat viral infections [0m[1;31m([0m[31me.g., the common cold[0m[1;31m)[0m[31m. When Ery-Ped is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better [0m
[31mearly in the course of therapy, the medication should be taken exactly as directed. ERYTHROMYCIN ETHYLSUCCINATE: precautions: Skipping doses or not completing the full course of therapy may [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m [0m
[31mdecrease the effectiveness of the immediate treatment and [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m increase the likelihood that bacteria will develop resistance and will not be treatable by Ery-Ped or other antibacterial drugs in the [0m
[31mfuture. Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and [0m
[31mbloody stools [0m[1;31m([0m[31mwith or without stomach cramps and fever[0m[1;31m)[0m[31m even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician [0m
[31mas soon as possible. Drug Interactions Theophylline Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and [0m
[31mpotential theophylline toxicity. ERYTHROMYCIN ETHYLSUCCINATE: precautions: In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while [0m
[31mthe patient is receiving concomitant erythromycin therapy. There have been published reports suggesting that when oral erythromycin is given concurrently with theophylline there is a decrease in [0m
[31merythromycin serum concentrations of approximately [0m[1;31m35[0m[31m%. The mechanism by which this interaction occurs is unknown. The decrease in erythromycin concentrations due to co-administration of theophylline [0m
[31mcould result in subtherapeutic concentrations of erythromycin. Hypotension, bradyarrhythmias, and lactic acidosis have been observed in patients receiving concurrent verapamil, belonging to the [0m
[31mcalcium channel blockers drug class. Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels. ERYTHROMYCIN ETHYLSUCCINATE: precautions: [0m
[31mThere have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly. Increased anticoagulation effects due to interactions of erythromycin with[0m
[31mvarious oral anticoagulants may be more pronounced in the elderly. Erythromycin is a substrate and inhibitor of the 3A isoform subfamily of the cytochrome p450 enzyme system [0m[1;31m([0m[31mCYP3A[0m[1;31m)[0m[31m. Coadministration [0m
[31mof erythromycin and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both the therapeutic and adverse effects of the [0m
[31mconcomitant drug. Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored closely in patients concurrently receiving [0m
[31merythromycin. The following are examples of some clinically significant CYP3A based drug interactions. ERYTHROMYCIN ETHYLSUCCINATE: precautions: Interactions with other drugs metabolized by the CYP3A [0m
[31misoform are also possible. The following CYP3A based drug interactions have been observed with erythromycin products in post-marketing experience: Ergotamine/dihydroergotamine Post-marketing reports [0m
[31mindicate that co-administration of erythromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other [0m
[31mtissues including the central nervous system. Concomitant administration of erythromycin with ergotamine or dihydroergotamine is contraindicated [0m[1;31m([0m[31msee CONTRAINDICATIONS [0m[1;31m)[0m[31m. ERYTHROMYCIN ETHYLSUCCINATE: [0m
[31mprecautions: Triazolobenzodiazepines [0m[1;31m([0m[31msuch as triazolam and alprazolam[0m[1;31m)[0m[31m and Related Benzodiazepines Erythromycin has been reported to decrease the clearance of triazolam and midazolam, and thus, may [0m
[31mincrease the pharmacologic effect of these benzodiazepines. HMG-CoA Reductase Inhibitors Erythromycin has been reported to increase concentrations of HMG-CoA reductase inhibitors [0m[1;31m([0m[31me.g., lovastatin and[0m
[31msimvastatin[0m[1;31m)[0m[31m. Rare reports of rhabdomyolysis have been reported in patients taking these drugs concomitantly. Sildenafil [0m[1;31m([0m[31mViagra[0m[1;31m)[0m[31m Erythromycin has been reported to increase the systemic exposure [0m[1;31m([0m[31mAUC[0m[1;31m)[0m
[31mof sildenafil. Reduction of sildenafil dosage should be considered. [0m[1;31m([0m[31mSee Viagra package insert. ERYTHROMYCIN ETHYLSUCCINATE: precautions: There have been spontaneous or published reports of CYP3A [0m
[31mbased interactions of erythromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine, and bromocriptine. [0m
[31mConcomitant administration of erythromycin with cisapride, pimozide, astemizole, or terfenadine is contraindicated. [0m[1;31m([0m[31mSee CONTRAINDICATIONS .[0m[1;31m)[0m[31m In addition, there have been reports of interactions of [0m
[31merythromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate. ERYTHROMYCIN ETHYLSUCCINATE: precautions: Erythromycin has been reported to [0m
[31msignificantly alter the metabolism of the nonsedating antihistamines terfenadine and astemizole when taken concomitantly. Rare cases of serious cardiovascular adverse events, including [0m
[31melectrocardiographic QT/QT c interval prolongation, cardiac arrest, torsades de pointes, and other ventricular arrhythmias have been observed. [0m[1;31m([0m[31mSee CONTRAINDICATIONS .[0m[1;31m)[0m[31m In addition, deaths have been [0m
[31mreported rarely with concomitant administration of terfenadine and erythromycin. There have been post-marketing reports of drug interactions when erythromycin was co-administered with cisapride, [0m
[31mresulting in QT prolongation, cardiac arrhythmias, ventricular tachycardia, ventricular fibrillation, and torsades de pointes most likely due to the inhibition of hepatic metabolism of cisapride by [0m
[31merythromycin. Fatalities have been reported.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: references: REFERENCES Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart [0m
[31mAssociation: Prevention of Rheumatic Fever. Circulation. [0m[1;31m78[0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m:[0m[1;31m1082[0m[31m-[0m[1;31m1086[0m[31m, October [0m[1;31m1988[0m[31m. Honein, M.A., et al.: Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: a [0m
[31mcase review and cohort study. ERYTHROMYCIN ETHYLSUCCINATE: references: The Lancet [0m[1;31m1999[0m[31m;[0m[1;31m354[0m[31m [0m[1;31m([0m[1;31m9196[0m[1;31m)[0m[31m: [0m[1;31m2101[0m[31m-[0m[1;31m5[0m[31m         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Erythromycin Ethylsuccinate has been reported to increase the anticoagulant effects when used concomitantly with oral anticoagulants. This interaction may be more pronounced in the elderly. [0m
[32mTherefore, it can be inferred that Erythromycin Ethylsuccinate may increase the risk of bleeding when used with oral anticoagulants.[0m

[32mSOURCE: ERYTHROMYCIN ETHYLSUCCINATE label[0m
[32mEXTRACT_START_END: There have been reports of increased anticoagulant effects[0m[32m...[0m[32m more pronounced in the elderly.[0m
*[1m([0morchestrator-bleeding-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Erythromycin Ethylsuccinate has been reported to [0m
[34mincrease the anticoagulant effects when used concomitantly with oral anticoagulants. This interaction may be more pronounced in the elderly. Therefore, it can be inferred that Erythromycin [0m
[34mEthylsuccinate may increase the risk of bleeding when used with oral anticoagulants.[0m

[34mSOURCE: ERYTHROMYCIN ETHYLSUCCINATE label[0m
[34mEXTRACT_START_END: There have been reports of increased anticoagulant effects[0m[34m...[0m[34m more pronounced in the elderly.[0m
 [1m([0morchestrator-bleeding-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-bleeding-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether ERYTHROMYCIN ETHYLSUCCINATE increases or decreases the risk of bleeding."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that Erythromycin Ethylsuccinate has been reported to increase the anticoagulant effects when used concomitantly with oral anticoagulants, which may be more pronounced in [0m
[32mthe elderly. Therefore, it can increase the risk of bleeding when used with oral anticoagulants."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"ERYTHROMYCIN ETHYLSUCCINATE may increase the risk of bleeding when used with oral anticoagulants, especially in the elderly."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-bleeding-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-bleeding-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the risk of bleeding?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether ERYTHROMYCIN ETHYLSUCCINATE increases or decreases the risk of bleeding."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that Erythromycin Ethylsuccinate has been reported to increase the anticoagulant effects when used concomitantly with oral anticoagulants, which may be more pronounced in [0m
[34mthe elderly. Therefore, it can increase the risk of bleeding when used with oral anticoagulants."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"ERYTHROMYCIN ETHYLSUCCINATE may increase the risk of bleeding when used with oral anticoagulants, especially in the elderly."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the risk of bleeding?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether ERYTHROMYCIN ETHYLSUCCINATE increases or decreases the risk of bleeding.[0m
[1;31m2[0m[31m. FDAHandler responded that Erythromycin Ethylsuccinate has been reported to increase the anticoagulant effects when used concomitantly with oral anticoagulants, which may be more pronounced in the [0m
[31melderly. Therefore, it can increase the risk of bleeding when used with oral anticoagulants.[0m
[31m        -----[0m
[31m        Final answer: ERYTHROMYCIN ETHYLSUCCINATE may increase the risk of bleeding when used with oral anticoagulants, especially in the elderly.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-bleeding-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-bleeding-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-bleeding-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-bleeding-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-bleeding-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe question was whether ERYTHROMYCIN ETHYLSUCCINATE increases or decreases the risk of bleeding. Based on the information provided by FDAHandler, Erythromycin Ethylsuccinate has been reported to [0m
[32mincrease the anticoagulant effects when used concomitantly with oral anticoagulants, which can be more pronounced in the elderly. Therefore, ERYTHROMYCIN ETHYLSUCCINATE may increase the risk of [0m
[32mbleeding when used with oral anticoagulants, especially in the elderly.[0m
